Clinical Advisory Panel

Minomic draws upon the expertise of five internationally esteemed medical experts on its Clinical Advisory Panel
Professor David Gillatt (Chair)

Professor David Gillatt (Chair)

Macquarie University Hospital, Australia

Professor Gillatt is a leading prostate and bladder cancer surgeon with more than 20 years’ experience. He is Director of Medical Services at Macquarie University Hospital and an adviser to health care, medical device, and global pharmaceutical companies. He specializes in urology and nephrology.

Dr Neal Shore

Dr Neal Shore

Carolina Urologic Research Center and Atlantic Urology Clinics, USA

Neal is an internationally recognized clinical researcher, working on innovative therapies for patients suffering prostate enlargement in the USA. His extensive research has included more than 150 clinical studies mainly focused on prostate and bladder disease. He is President of LUGPA and Director of Carolina Urologic Research Centre.

Professor Daniel W. Chan

Professor Daniel W. Chan

Johns Hopkins University and Johns Hopkins Hospital, USA

Professor Chan is Director of The Center for Biomarker Discovery and Translation and Professor of Pathology, Oncology, Radiology and Urology at Johns Hopkins University. He is also the Director of the Clinical Chemistry Division and Co-Director of the Pathology Core Laboratory at the Johns Hopkins Hospital. He is an internationally recognized expert in cancer biomarkers, clinical proteomics, and molecular diagnostics.

Professor John Babich

Professor John Babich

Weill Cornell Medical College, USA

John is Professor of Radiopharmaceutical Sciences in Radiology at the Weill Cornell Medical College in New York. He specializes in radiology and oncology and is widely published, authoring more than 200 clinical research articles.

Professor Mark Emberton

Professor Mark Emberton

University College London, UK

Professor Emberton is Dean of the Faculty of Medical Science at University College London. He leads a clinical innovation team that combines bioengineering and nanotechnology with early phase trials in men with prostate cancer. His work encompasses diagnosis, risk stratification, and therapy.